Refractory Epilepsy- Pipeline Insight, 2019

"Refractory Epilepsy- Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Refractory Epilepsy pipeline landscape is provided which includes the disease overview and Refractory Epilepsy treatment guidelines. The assessment part of the report embraces, in depth Refractory Epilepsy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Refractory Epilepsy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Refractory Epilepsy Understanding
Patients with epilepsy whose seizures do not successfully respond to anti-seizure drug therapy are considered to have Refractory Epilepsy. This condition is also referred to as intractable, drug-resistant, or pharmacoresistant epilepsy. Refractory or uncontrolled epilepsy is a heavy burden. According to Epilepsy Foundation, in the United States, approximately 3.4 million people live with epilepsy, and over 150,000 new cases are diagnosed each year. One in 26 people will develop epilepsy at some point in their life. Epilepsy doesn’t discriminate. If affects children and adults, men and women, and people of all races, religions, ethnic backgrounds, and social classes. While epilepsy is most often diagnosed either in childhood or after the age of 65, it can occur at any age. The common triggers of epilepsy include Sleep deprivation, overtired, not sleeping well, not getting enough sleep, flashing bright lights or patterns, alcohol consumption, stress, low blood sugar, etc.
Refractory Epilepsy Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Refractory Epilepsy targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Refractory Epilepsy pipeline report covers 8+ companies. Some of the key players include UCB Biopharma (Padsevonil (UCB0942)), Aquestive Therapeutics (AQST-203), PTC Therapeutics (Ataluren) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Refractory Epilepsy Analytical Perspective by DelveInsight
• In-depth Refractory Epilepsy Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
• Refractory Epilepsy Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
• The Refractory Epilepsy report provides an overview of therapeutic pipeline activity for Refractory Epilepsy across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Refractory Epilepsy therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
• Detailed Refractory Epilepsy Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Refractory Epilepsy
Reasons to Buy
• Establish a comprehensive understanding of the current pipeline scenario across Refractory Epilepsy to formulate effective R&D strategies
• Assess challenges and opportunities that influence Refractory Epilepsy R&D
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Get in detail information of each product with updated information on each project along with key milestones
• Devise Refractory Epilepsy in licensing and out licensing strategies by identifying prospective partners with progressing projects for Refractory Epilepsy to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs